Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zai Lab Ltd ( (HK:9688) ) has provided an announcement.
Zai Lab Limited announced the filing of its Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, with the U.S. Securities and Exchange Commission. This filing is part of the company’s regulatory compliance and provides stakeholders with updated financial and operational information, potentially impacting investor confidence and market positioning.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, with a focus on developing and commercializing innovative therapies. The company operates in the healthcare industry, primarily targeting cancer, autoimmune disorders, and infectious diseases, with a market focus on China and the United States.
Average Trading Volume: 14,692,157
Technical Sentiment Signal: Sell
Current Market Cap: HK$23B
Find detailed analytics on 9688 stock on TipRanks’ Stock Analysis page.